TP53 and cancer: In fact, several low-molecular-weight compounds that have been shown to block the binding between p53 and MDM2 (e.g., Nutlin-3a) have also been shown to improve the response to anticancer drugs in cancer cells in vitro (Cheok et al., 2011; Guo et al., 2017; Essmann et al., 2012).